九价HPV疫苗在27-45岁与16-26岁女性中的免疫原性与安全性
这项国际开放标签3期研究纳入16-26岁570人和27-45岁642人女性,按0、2、6月接种三剂九价HPV疫苗。27-45岁女性第7月抗HPV 16/18/31/33/45/52/58型GMT相对16-26岁女性达到非劣效,各型抗体阳转率均>99%,两组不良事件谱相似,未见疫苗相关严重不良事件。
要点
- 27-45岁女性接种九价HPV疫苗后抗体GMT对7种高危型达非劣效
- 27-45岁女性第7月各型抗体阳转率均>99%
- 两组不良事件谱相似,未报告疫苗相关严重不良事件
核心结论
- 九价HPV疫苗在27-45岁女性中诱导的抗HPV 16/18/31/33/45/52/58型GMT非劣于16-26岁女性。
- 疫苗总体耐受性良好,两个年龄组不良事件谱相似。
- 上述数据支持将16-26岁女性的九价HPV疫苗效力结果外推至27-45岁女性。
研究设计与样本
- 国际、开放标签3期研究(NCT03158220),受试者为16-45岁女性。
- 16-26岁组n=570,27-45岁组n=642,均按第1天、第2月、第6月接种三剂九价HPV疫苗。
- 第7月评估抗HPV 6/11/16/18/31/33/45/52/58型几何平均滴度(GMT)与抗体阳转率,并全程随访安全性。
主要发现
- 主要假设为27-45岁女性抗HPV 16/18/31/33/45/52/58型GMT相对16-26岁女性非劣效,该假设达成。
- GMT比值(27-45岁比16-26岁)95%CI下限随HPV型别为0.60-0.67,均超过非劣效界值0.5。
- 27-45岁女性第7月各HPV型别抗体阳转率均>99%。
- 注射部位不良事件在16-26岁与27-45岁女性中分别为87.5%和85.2%,疫苗相关全身不良事件分别为25.1%和24.1%。
- 未报告疫苗相关严重不良事件,研究期间无死亡发生。
关键数值与推荐
- 非劣效界值为GMT比值95%CI下限0.5。
- 27-45岁比16-26岁GMT比值95%CI下限为0.60-0.67(依HPV型别)。
- 27-45岁女性第7月各型抗体阳转率>99%。
临床怎么用
- 提示27-45岁女性可按0、2、6月三剂程序接种九价HPV疫苗,免疫应答不劣于16-26岁女性。
- 接种前咨询可告知注射部位不良事件较常见、全身不良事件约四分之一、疫苗相关严重不良事件未见报告。
- 研究结果支持将 younger 年龄组的效力证据桥接用于27-45岁女性的接种决策。
局限性
- 为开放标签设计,未设安慰剂对照。
- 免疫原性为非劣效桥接,未直接评估27-45岁女性的疫苗效力。
- 安全性随访限于研究期间,长期安全性未在本文报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types 6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16-26 years of age. We present a phase 3 immunogenicity and safety study of the 9vHPV vaccine in women 27-45 versus 16-26 years of age. METHODS: This international, open-label study (NCT03158220) was conducted in women 16-45 years of age. Participants (16-26 years, n = 570 and 27-45 years, n = 642) received a three-dose 9vHPV vaccination regimen (day 1, month 2, month 6). Month 7 geometric mean titers (GMTs) and seroconversion percentages to anti-HPV 6/11/16/18/31/33/45/52/58 were assessed. Participants were followed for safety throughout the study. RESULTS: At month 7, anti-HPV 6/11/16/18/31/33/45/52/58 GMTs in women 27-45 years were compared to those in women 16-26 years of age. The primary hypothesis of non-inferiority of anti-HPV 16/18/31/33/45/52/58 GMTs in older versus younger women was met. The lower bound of the GMT ratio 95% confidence interval (27-45 years to 16-26 years) was 0.60-0.67 depending on HPV type, exceeding the non-inferiority margin of 0.5 for all HPV types. Month 7 seroconversion percentages in women 27-45 years of age were >99% for all HPV types. Injection-site and vaccine-related systemic adverse events (AEs) were observed in 87.5% and 25.1% of women 16-26 years, and 85.2% and 24.1% of women 27-45 years of age, respectively; no vaccine-related serious AEs were reported and no deaths occurred during the study. CONCLUSIONS: The 9vHPV vaccine elicited non-inferior anti-HPV GMTs in women 27-45 years compared with women 16-26 years of age for HPV 16/18/31/33/45/52/58. The vaccine was generally well tolerated with a similar AE profile across the age groups. These data support bridging 9vHPV vaccine efficacy findings in women 16-26 years to women 27-45 years of age. Clinical trial registration NCT03158220.
引用
- Joura EA, Ulied A, Vandermeulen C, et al. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. Vaccine. 2021. PMID: 33676783. doi:10.1016/j.vaccine.2021.01.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。